Authors
Latest:
Courtney DiNardo, MD, on Looking Forward in AML TreatmentThe MD Anderson Cancer Center expert discussed the future of acute myeloid leukemia treatment, and how the field is evolving rapidly.
Latest:
Kelly Morgan, MS, CGC, the Future of Telemedicine and Genetic TestingThe MSK expert discussed how telemedicine may change genetic testing and its access for patients.
Latest:
Matthew Steven Davids, MD, MMSc, on the Venetoclax, R-EPOCH Combo for Richter’s SyndromeThe CLL expert spoke about the implications of this study for patients and how patients can apply this knowledge to their own course of treatment.
Latest:
Thierry André, MD, on Interim Results from the Phase III Keynote-177 StudyThe findings, presented at the 2020 ASCO Virtual Scientific Program, are the first to show benefit with pembrolizumab in patients with advanced colorectal cancer when used as a front-line therapy.
Latest:
Benoit You, MD, PhD, on the use of Avelumab to Treat Patients With Gestational Trophoblastic TumorsThe expert from the Centre Hospitalier Lyon-Sud discussed the results of a phase II study of avelumab for patients with GTT who were resistant to chemotherapy.
Latest:
John Kuruvilla, MD, Discusses Toxicities Observed in the Phase 3 KEYNOTE-204 StudyThe expert in hematology highlighted the toxicities reported in this trial and explained the differences observed between the 2 drugs studied.
Latest:
Dosing Lenvatinib for Treatment of Advanced Renal Cell CarcinomaKidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.
Latest:
Sacituzumab Govitecan Yields Improved Survival Regardless of Trop-2 Levels for HR+/HER2– Breast CancerImprovements in survival were observed in patients with pretreated, endocrine-resistant hormone receptor–positive, HER2-negative metastatic breast cancer who were treated with sacituzumab govitecan vs physician’s choice.
Latest:
Andres Poveda, MD, on the Implications of the Phase 3 SOLO2/ENGOT-ov21 TrialThe expert in ovarian cancer indicated that treatment with the studied maintenance olaparib tablets could aid patients in having a more regular lifestyle.
Latest:
Ruxolitinib Plus Standard Prophylaxis Lowers GVHD Risk in MyelofibrosisRuxolitinib shows promise in improving transplant outcomes for myelofibrosis patients by reducing GVHD incidence without compromising survival.
Latest:
Promising Clinical Activity in UTUC Lesions With Enfortumab Vedotin Plus PembrolizumabNew data from a small retrospective analysis showed activity with enfortumab vedotin and pembrolizumab in UTUC lesions.
Latest:
Maintaining Docetaxel Dose Intensity in mHSPC with G-CSF in ARASENS RegimenPhase 3 ARASENS trial results highlight the role of G-CSF in optimizing docetaxel delivery within the darolutamide-based regimen for mHSPC.
Latest:
ASCO Expert on the Possible Benchmark Analysis of Autologous Transplantation in B-Cell LymphomasNirav Niranjan Shah, MD, discussed the analysis of autologous transplantation use in patients with relapsed, chemosensitive DLBCL and how it may become a comparator for other clinical trials.
Latest:
Cross Q&A: The Memorial Sloan-Kettering MavericksThe Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Latest:
The Role of Autologous Stem Cell Transplantation in AmyloidosisAutologous stem cell transplantation has been an essential part of the treatment armamentarium in light chain amyloidosis for several decades. This review provides a comprehensive assessment of eligibility criteria for ASCT in AL amyloidosis, conditioning dosing, efficacy in terms of hematologic and organ response, and future areas of research.
Latest:
Martin Reck, MD, PhD, Discusses NSCLC Data of Interest From 2021 ASCOReck mentioned the IMpower010 and CheckMate 816 trials investigating treatment options for patients with non-small cell lung cancer.
Latest:
Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022Closing out their discussion, the panel highlights unmet needs in multiple myeloma that clinicians and patients still face.
Latest:
CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive DiseasePanelists discuss how, when selecting a chimeric antigen receptor T-cell (CAR T) product for a patient with an aggressive clinical course and eligibility for cellular therapy, key considerations include urgency, toxicity risks, and efficacy. Factors such as time to manufacture, cytokine release syndrome/immune effector cell–associated neurotoxicity syndrome rates, long-term remission data, and antigen specificity guide decision-making.
Latest:
Advanced Penile Cancer Presenting With Renal Failure“MK,” a man aged 67 years, presented with fatigue and nausea to his primary care physician. CT staging scans confirmed the primary tumor and a suspicious left 1.2-cm inguinal lymph node but no distant metastases. MRI of the pelvis revealed complete replacement of the penis with tumor as well as invasion into the scrotum and bilateral groin soft tissue; additionally, early pubic bone invasion was present, with left groin lymphadenopathy. Biopsy verified squamous cell carcinoma of the penis, and discussion with the multidisciplinary team uroradiologist confirmed bony invasion.
Latest:
SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer CarePaolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.
Latest:
PI3K Inhibitors, Oral SERDs, Combination Therapies, and the Shifting Treatment LandscapePanelists discuss ongoing clinical trials and how the treatment landscape for HR positive (HR+)/ HER2 negative (HER2-) breast cancer is evolving with novel targeted therapies and combination strategies, with Dr Isaacs highlighting the most exciting aspects of these trials and their potential impact on the future of precision medicine in this patient population.
Latest:
Ronnie Shapira-Frommer, MD, Discusses Multidisciplinary Care to Treat Gynecologic MalignanciesCancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about her thoughts on the effect of the conference content across multidisciplinary specialties.
Latest:
Treatment of Locally Advanced Cervical Cancer With Kidney Failure and ComorbiditiesIn this edition of Clinical Quandaries Eder A. Arango Bravo, MD, and colleagues present a 63 year old woman who has cervical cancer with kidney failure and additional comorbidities.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Phyllis Morgan on Health Disparities in Patients At Risk for Developing Colorectal CancerPhyllis Morgan, PhD, sat down with CancerNetwork® to discuss health disparities during Colorectal Cancer Awareness Month.
Latest:
Data Support Liso-cel as an ‘Important’ Therapy in Relapsed/Refractory CLLTreatment with lisocabtagene maraleucel in the TRANSCEND CLL 004 study raises no new safety concerns in patients with relapsed/refractory chronic lymphocytic leukemia, says Tatyana Feldman, MD.
Latest:
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited SettingA recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting.
